Abstract:Abstract MAPK pathway activation is a feature of multiple tumor types. Drugging KRAS and BRAF, the two main oncogenic drivers in the MAPK pathway, has proven successful in the clinic. Inhibition of the downstream effectors, MEK and ERK, can also induce tumor regression. Despite this, many tumors are intrinsically resistant to MAPK pathway inhibitors, or acquire resistance under selective pressure to drug treatment. This creates a need for combination treatments to improve clinical responses. A synthetic lethal (SL) interaction between inhibition of the MAPK pathway and blockade of JNK-JUN signaling has recently been described1. Specifically, data from yeast genetics and CRISPR knockout experiments in human cells have identified MAP2K4 as a potential therapeutic target that could be combined with MAPK inhibitors. To date, however, no potent MAP2K4 inhibitors with in vitro and cellular selectivity against key anti-targets have been reported. Here, we describe the development of potent covalent inhibitors of MAP2K4 kinase activity. Biochemical and cell-based assays show that the compound(s) are selective for MAP2K4 versus anti-targets including MAP2K7 and ERK kinases. The combination of MAP2K4 and MEK/ERK inhibitors was effective in cell lines driven by MAPK signaling. These data provide the rationale for further development of MAP2K4 inhibitors to advance our understanding of this novel drug combination. References: 1. Xue Z, Vis DJ, Bruna A, Sustic T, van Wageningen S, Batra AS, et al. MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell Res. 2018; 28:719-29. Citation Format: Mark Wade, Emiliano Tamanini, Mathieu Unbekandt, Nicola Wallis, John Lyons, Joanne Munck, Andrew Woodhead, Patrick Schopf, Jessie Stow, Charlotte East, Mellissa Clark, Jeffrey St. Denis, Puja Pathuri. Targeting MAPK-driven tumors via inhibition of MAP2K4 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5902.

Identification of Interaction Between MEK2 and A-Raf-1.

Identi ¢ cation of interaction between MEK 2 and ARaf-1

Identification of TH1 as an interaction partner of A-Raf kinase

Identification and Biological Evaluation of Novel Type II B-Raf V600E Inhibitors.

In Silico Identification of Novel Kinase Inhibitors by Targeting B-Rafv660e from Natural Products Database

Activating Mutations in MEK1 Enhance Homodimerization and Promote Tumorigenesis.

Proteomic characterization of the dynamic KSR-2 interactome, a signaling scaffold complex in MAPK pathway

Revealing A-Raf Functions Through Its Interactome

Scaffolding mechanism of arrestin-2 in the cRaf/MEK1/ERK signaling cascade

MEK-2, a Caenorhabditis elegans MAP kinase kinase, functions in Ras-mediated vulval induction and other developmental events

Identification of extracellular signal-regulated kinase 3 as a new interaction partner of cyclin D3

Characterization of the Structure and Function of a Novel MAP Kinase Kinase (MKK6)

The Kinase Activity-deficient Isoform of the Protein Araf Antagonizes Ras/Mitogen-activated Protein Kinase (ras/mapk) Signaling in the Zebrafish Embryo

Abstract 5902: Targeting MAPK-driven tumors via inhibition of MAP2K4

Mip1, an MEKK2-Interacting Protein, Controls MEKK2 Dimerization and Activation

The Dimer-Dependent Catalytic Activity of RAF Family Kinases is Revealed Through Characterizing Their Oncogenic Mutants

Dual Inhibition of Allosteric Mitogen-Activated Protein Kinase (MEK) and Phosphatidylinositol 3-Kinase (PI3K) Oncogenic Targets with a Bifunctional Inhibitor

The Activation of MEK1 by Enhanced Homodimerization Drives Tumorigenesis

Characterization of ATP-independent ERK Inhibitors Identified Through in Silico Analysis of the Active ERK2 Structure.

Characterization and Functional Analysis of Grouper (epinephelus Coioides) MEK1 and MEK2

Dimerization Through the Catalytic Domain is Essential for MEKK2 Activation